Boundless Bio (BOLD)

• Market cap: $26M
• 1 day: 0%
• 5 days: -0.85%
• 1 month: -4.92%
• 3 months: -0.85%
• 6 months: 1.75%
• Year to date: -4.92%
• 1 year: -38.95%
• 5 years: -91.86%
• 10 years: -91.86%
• Sector: Healthcare
• Industry: Biotechnology

About: Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 64